Details

Autor(en) / Beteiligte

• Lamb, Sarah A.
• Al Hamarneh, Yazid N.
• Houle, Sherilyn K. D.
• Leung, Alexander A.
• Tsuyuki, Ross T.

Titel

Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults for pharmacists: An update

Ist Teil von

• Canadian pharmacists journal, 2018-01, Vol.151 (1), p.33-42

Ort / Verlag

Los Angeles, CA: SAGE Publications

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Changes to 2017 Hypertension Canada guidelines relevant to pharmacists Assess adherence to therapy at every patient encounter Use a multidisciplinary team approach, including work-site health care providers, to improve adherence Evidence for pharmacist-led interventions The pharmacists’ role in chronic disease management is becoming increasingly prominent as a result of an expanded scope of practice and the growing strain on the health care system. A systematic review and meta-analysis of 39 randomized controlled trials comprising over 14,000 patients showed that pharmacists’ interventions—namely, patient education, recommendations to physicians and medication management—resulted in greater reductions of both SBP (−7.6 mmHg; 95% CI, –9 to −6.3) and DBP (−3.9 mmHg; 95% CI, −5.1 to −2.8) compared with usual care.9 Interestingly, the most pronounced effect on blood pressure reduction was seen when the pharmacist led the intervention, resulting in a SBP reduction of –8.5 mmHg and a DBP reduction of –4.6 mmHg. Results from the RxACTION trial demonstrated an even greater effect on blood pressure reduction when pharmacist interventions included independent prescribing for hypertension (mean SBP reduction 18.3 mmHg, adjusted difference 6.6 mmHg).10 In addition, patients in the pharmacist prescribing arm were 2.3 times more likely to achieve target blood pressures.